Image of Laurent Fischer, M.D.

Dr. Fischer joined Tobira's board of directors in April 2009 and became chief executive officer in 2014. Dr. Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time he was chairman and chief executive officer of Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics (OCRX), where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa®, the first treatment approved for Irritable Bowel Syndrome in Europe. Dr. Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Dr. Fischer was responsible for the Global launch of Sustiva® the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla® and was involved in the launch of Invirase®, the first protease inhibitor, in the United States. Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Image of Eric Lefebvre, M.D.

Dr. Lefebvre joined Tobira in January 2012 as chief medical officer. He brings to Tobira 25 years of pharmaceutical industry, clinical care and research experience in virology. Before joining Tobira, he was the global medical affairs leader at Janssen Pharmaceuticals, a Johnson & Johnson company, where he championed the clinical development, publication and commercialization optimization plans for Prezista®, Intelence®, Edurant® and Olysio™. Prior to his tenure at Janssen, Dr. Lefebvre was medical advisor for the HIV, HSV vaccines and hepatitis therapeutic areas at GlaxoSmithKline, Canada. His career in industry was preceded by 15 years of providing primary care at Clinique Médicale L'Actuel in Montréal, where he specialized in the prevention, diagnosis and treatment of STDs (including HSV and HPV), HIV/AIDS and hepatitis. A member of the Canadian HIV Trials Network and Canadian Association for HIV Research, Dr. Lefebvre was the principal or co-investigator in multiple Phase 3 and 4 trials focused on STDs and HIV/AIDS. He has published numerous articles and scientific guides, and is a frequent presenter at medical conferences on HIV/AIDS disease progression, antiretroviral therapy and STDs. Dr. Lefebvre received his medical degree from the University of Montréal.

Image of Christopher Peetz

Mr. Peetz joined Tobira as chief financial officer and head of corporate development in 2014. Prior to joining Tobira, Mr. Peetz was vice president, finance & corporate development at Jennerex, Inc. While at Jennerex, Mr. Peetz led a $21 million private financing and the sale of the company to SillaJen for $150 million including milestones. Prior to Jennerex, Mr. Peetz was at Onyx Pharmaceuticals, Inc. (now Amgen), and had oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles on Nexavar®, Stivarga® and Kyprolis®. While at Onyx, Mr. Peetz supported public financings totaling nearly $300 million. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix, Inc. and Solazyme, Inc. Mr. Peetz received an MBA from Stanford Graduate School of Business and BSBA from Washington University in St. Louis.

Image of Helen Jenkins

Ms. Jenkins joined Tobira in August 2011 as senior vice president, program leadership. She brings to Tobira more than 25 years of drug development experience, most recently at Nuon Therapeutics, Inc., and Saegis Pharmaceuticals, Inc., where, as a corporate officer, she was responsible for development operations, strategic planning and portfolio management. Prior to Nuon and Saegis, Ms. Jenkins was senior director, product development/regulatory affairs, at Valentis, Inc., where she served as primary liaison with pharmaceutical partners and managed two preclinical gene therapy candidates through IND. Ms. Jenkins also led preclinical programs through successful IND filings during her tenures at Glycomed Inc. and Genentech, Inc. She has a Bachelor of Science in biochemistry from California Polytechnic State University, San Luis Obispo and a Masters of Arts in cellular and molecular biology from San Francisco State University.

Image of Ian Clements, Ph.D.

Dr. Clements joined Tobira in July 2015 and directs investor relations, corporate communications and media relations activities. Dr. Clements has over 20 years of industry and communications experience. Most recently he led investor relations and corporate communications at Avanir Pharmaceuticals, Inc. where he expanded the investor relations program, up until the company’s acquisition by Otsuka Pharmaceutical. Prior to that, he headed investor relations and corporate communications at Sequenom, Inc. Dr. Clements also held positions at the Trout Group, an investor relations agency, and at Accelrys, Inc. He holds a Ph.D. in chemistry from the University of Manchester and an M.B.A. from the Open University in the U.K.